Emerging Therapies for the Myelodysplastic Syndromes
- 10.2991/chi.d.191202.001How to use a DOI?
- Myelodysplastic syndromes
Despite considerable advances in our understanding of the molecular and epigenetic underpinnings of the myelodysplastic syndromes (MDS), this diverse group of myeloid neoplasms remains a significant clinical challenge. Considerable barriers to timely development of effective therapy include the diverse molecular landscape encountered in MDS patients, the difficulty in translating specific molecular aberration into a clinically meaningful animal model, as well as challenges in patient recruitment into clinical trials. These speak to the need to discover efficacious novel therapeutic targets which would in turn translate into improved patient outcomes in terms of both survival and quality of life. In this review, we outline recently published data pertaining to therapeutic advances in TGF-β pathway inhibition, STAT3, Hedgehog signaling, and additional therapeutic venues being actively explored in MDS.
- © 2019 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
- Open Access
- This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
Download article (PDF)
View full text (HTML)
Cite this article
TY - JOUR AU - Jonathan Canaani PY - 2019 DA - 2019/12/06 TI - Emerging Therapies for the Myelodysplastic Syndromes JO - Clinical Hematology International SP - 13 EP - 17 VL - 2 IS - 1 SN - 2590-0048 UR - https://doi.org/10.2991/chi.d.191202.001 DO - 10.2991/chi.d.191202.001 ID - Canaani2019 ER -